An intact microbiota is required for the gastrointestinal toxicity of the immunosuppressant mycophenolate mofetil

Mycophenolate mofetil (MMF) is commonly prescribed after transplantation and has important advantages over other immunosuppressive drugs but frequent gastrointestinal (GI) side effects limit its use. The mechanism(s) underlying MMF-related GI toxicity have yet to be elucidated.

Source: The Journal of Heart and Lung Transplantation - May 23, 2018 Category: Transplant Surgery Authors: Kyle L. Flannigan, Michael R. Taylor, Sheldon K. Pereira, Jimena Rodriguez-Arguello, Andrew W. Moffat, Laurie Alston, Xuemei Wang, Karen K. Poon, Paul L. Beck, Kevin P Rioux, Mahesh Jonnalagadda, Prasanth K. Chelikani, Heather J Galipeau, Ian A. Lewis, Ma Tags: Original Pre-clinical Science Source Type: research